VIP peptide
Reviewed
Short answer
VIP is a natural 28-amino-acid body signal. A trial of synthetic VIP did not establish a treatment benefit. Human physiology and a clinical trial have been studied; product approval needs a separate current check.
This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Read the study findingsAlso known as Vasoactive intestinal peptide · Vasoactive intestinal polypeptide
Study and product details
What it is
VIP means vasoactive intestinal peptide. It is a natural body signal made from 28 amino acids. It affects blood vessels and other body systems. Aviptadil is synthetic VIP used in specific research studies. A natural body signal and a finished drug product are different things.
Type of peptide: Natural body signal. This describes what the substance is or how it works. It does not show that it is safe, effective, or approved.
What has been studied?
- Limited: Research is too small or incomplete, or does not directly answer this question.
- Unclear: There is not enough reliable detail about the product or research to judge.
A 196-person aviptadil trial in critical COVID-19 respiratory failure missed its prespecified day-60 primary endpoint. Other trial results do not prove a treatment benefit.
A 12-person healthy-volunteer study measured a short vascular response and delayed headache during and after VIP infusion.
The cited human studies cover specific research material and routes. They do not establish the safety of other VIP products or long-term use.
The checked FDA records identify a substance and two orphan designations. They do not establish approval, quality, or equivalence of a finished product.
Products with the same ingredient can differ.
The ingredient name does not tell you everything about a product. Check its other ingredients, its form, how it enters the body, and the use and people covered by the research or approval.
None identified in the United States.
No approved use.
What studies found
In 12 healthy volunteers, a two-hour VIP infusion widened a head artery and increased mild delayed headache. This measured a short body response, not a health benefit. A randomized trial studied intravenous aviptadil in 196 people with critical COVID-19 respiratory failure. Its main result was whether people were alive and free from respiratory failure at day 60. That primary result did not reach statistical significance. Some other results favored aviptadil, but they do not make the main result a success.
These studies do not show that VIP treats COVID-19, lung disease, gut disease, or aging. The trial did not test other routes or products. The FDA records checked here identify aviptadil and two orphan designations. Both designation records say the named orphan indication was not FDA approved. Those records do not establish the approval status of every possible product or use. They also do not show that an online or compounded item matches the trial material.
Which products do these findings apply to?
VIP is a natural body signal. Aviptadil is synthetic VIP studied as a defined intravenous research treatment. An FDA substance record or orphan designation is not approval of a finished drug. Neither record shows that a compounded or online product matches the trial material.
Fact checks
5 statements checked. Read what the results mean.
“VIP is a natural peptide made from 28 amino acids.”
The discovery report identifies a 28-residue intestinal peptide. This identity fact does not establish a human treatment.
- What this answer is based on
- Official record or product label
- Limits of this answer
- The natural vasoactive intestinal peptide, not a finished drug product.
Sources for this fact check (1)
“VIP infusion changed blood-vessel and headache measures in healthy people.”
A study of 12 healthy volunteers measured a short vascular response and delayed headache after a specified infusion. It did not test a disease treatment.
- What this answer is based on
- Studies of body changes in people
- Limits of this answer
- The 12-person healthy-volunteer study and its exact research route.
Sources for this fact check (1)
“Aviptadil proved effective for critical COVID-19 respiratory failure.”
The 196-person randomized trial did not meet its prespecified day-60 primary endpoint. Secondary and subgroup results cannot make the primary endpoint significant.
- What this answer is based on
- Health results from a study with randomly assigned groups
- Limits of this answer
- Intravenous aviptadil in the 2022 trial; no inference about another VIP product.
Sources for this fact check (1)
Show 2 more fact checks
“An FDA aviptadil substance record or orphan designation is drug approval.”
A substance record identifies a substance. The two checked FDA orphan records state that the named orphan indications were not approved. Neither record approves a finished product.
- What this answer is based on
- Official record or product label
- Limits of this answer
- The exact FDA records checked September 12, 2026; this is not a complete product-level approval search.
Sources for this fact check (3)
“A compounded or online VIP product matches the aviptadil trial material.”
The cited trial studied defined intravenous research material. The checked FDA records do not establish the identity, quality, route, or equivalence of another product.
- What this answer is based on
- No reliable studies showing this health result in people
- Limits of this answer
- Online and compounded products compared with the 2022 trial material.
Sources for this fact check (2)
Risks and safety limits
This page gives no dose, injection, sourcing, product-selection, or treatment advice. A short study response does not prove long-term safety or benefit. Ask a licensed clinician about personal care.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
Reviewed .Check the rules for athletes ↗Terms used in the studies
- clinical trial
- a planned study in people
- outcome
- what the study measured
- peptide
- a short chain of amino acids
- randomized
- assigned to study groups by chance
- route
- how the product enters the body
- indication
- the approved or studied use and patient group
- compounded
- made for one patient by a pharmacy, or in batches by a permitted outsourcing facility; a compounded drug is not FDA-approved
- amino acid
- a small building block that makes peptides and proteins
Read the sources
Show 8 sources
Review history
Reviewed the discovery report, a 12-person healthy-volunteer study, the 196-person aviptadil trial, and exact FDA substance and orphan-designation records. This is an internal source review, not independent medical review.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.
Report a factual error